Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

181. Diagnostic performance of HMGA2 gene expression for differentiation of malignant thyroid nodules: A systematic review and meta-analysis. (Abstract)

Diagnostic performance of HMGA2 gene expression for differentiation of malignant thyroid nodules: A systematic review and meta-analysis. The purpose of the current study was to investigate the diagnostic performance of high mobility group A2 (HMGA2) gene expression for differentiation of malignant thyroid nodules through a systematic review and meta-analysis.The MEDLINE/PubMed and EMBASE database, from the earliest available date of indexing through 10 April 2018, were searched for studies (...) evaluating the diagnostic performance of HMGA2 expression for differentiation of thyroid nodules.We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic (ROC) curves.Across 7 studies, the pooled sensitivity for HMGA2 expression was 0.78 (95% CI; 0.67-0.86) with heterogeneity (I2  = 86.6) and a pooled specificity of 0.94 (95% CI: 0.85-0.98) with heterogeneity (I2  = 94.7

2019 Clinical endocrinology

182. Significance of neck dissection for the treatment of clinically-evident medullary thyroid carcinomas: A systematic review. (Abstract)

Significance of neck dissection for the treatment of clinically-evident medullary thyroid carcinomas: A systematic review. The survival benefit of prophylactic lateral neck dissection in medullary thyroid carcinomas remains unclear; thus, recent clinical guidelines have deferred the recommendation of lateral neck dissection. This review is to assess the role of lateral neck dissection in treatment of clinically overt medullary thyroid carcinoma.A meta-analysis was performed on full-text

2019 Auris, nasus, larynx

183. Hyperfunctioning thyroid carcinoma: A systematic review. (Full text)

Hyperfunctioning thyroid carcinoma: A systematic review. Hyperthyroidism may be caused by the development of primary or metastatic thyroid carcinoma. The aim of the present study was to collect recently reported cases of hyperfunctioning thyroid carcinoma in order to analyze its pathological characteristics, diagnostic procedures and treatment strategies. A PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) search was performed for studies published between January 1990 and July 2017. Full-text (...) articles were identified using the terms, 'hyperfunctioning thyroid carcinoma/cancer', 'malignant hot/toxic thyroid nodule', or 'hyperfunctioning papillary/follicular/Hürthle thyroid carcinoma'. Original research papers, case reports and review articles were included. Among all thyroid carcinoma cases included in the present study, the prevalence of follicular thyroid carcinoma (FTC) was ~10%; however, the prevalence of FTC among hyperfunctioning thyroid carcinomas was markedly higher (46.5% in primary

2019 Molecular and clinical oncology PubMed abstract

184. Thyroid disease: assessment and management

Thyroid disease: assessment and management Thyroid disease: assessment and management NICE guideline Published: 20 November 2019 www.nice.org.uk/guidance/ng145 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Thyroid disease: assessment and management (NG145) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 53Contents Contents Overview 5 Who is it for? 5 Recommendations 6 1.1 Information for people

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

185. Thyroid hormones treatment for subclinical hypothyroidism (Full text)

Thyroid hormones treatment for subclinical hypothyroidism Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Thyroid hormones... Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline (Published 14 May 2019) Cite this as: BMJ 2019;365:l2006 Visual summary of recommendation or No thyroid hormones Thyroid hormones (...) Levothyroxine Interventions compared Recommendation Population Adults with subclinical hypothyroidism Does not apply to: May not apply to: Including: Women who are or trying to become pregnant Patients with no symptoms (diagnosed after screening) Patients with non-specific symptoms Patients with severe symptoms Patients with TSH above 20 mIU/L Young adults (such as <30 years) Elevated levels of thyroid stimulating hormone (TSH) Normal free T4 (thyroxine) levels We recommend against thyroid hormone therapy

2019 BMJ Rapid Recommendations PubMed abstract

186. Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V

Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lenvatinib (Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-19 Lenvatinib (...) (thyroid carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-19 Version 1.0 Lenvatinib (thyroid carcinoma) 13 May 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lenvatinib (thyroid carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 February 2019

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

187. Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma? (Abstract)

Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma? The incidence of papillary thyroid microcarcinoma (PTMC) has increased over the past decade. The American Thyroid Association (ATA) suggests that these patients may undergo either thyroid lobectomy or active surveillance. It remains unclear whether there exists a subgroup of PTMC patients who may benefit from more aggressive treatment due to increased risk of recurrence.We retrospectively reviewed 357

2019 EvidenceUpdates

188. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care

Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Richard Birtwhistle , Kate Morissette , James A. Dickinson , Donna L. Reynolds , Marc T. Avey , Francesca Reyes Domingo , Rachel Rodin (...) of Family Medicine and Community Health Sciences (Dickinson), University of Calgary, Alta.; Dalla Lana School of Public Health and Department of Family and Community Medicine (Reynolds), University of Toronto, Ont.; Department of Psychiatry (Thombs), Jewish General Hospital and McGill University, Montréal, Que. KEY POINTS The Canadian Task Force on Preventive Health Care strongly recommends against screening for thyroid dysfunction in asymptomatic nonpregnant adults. Screening for thyroid dysfunction

2019 Canadian Task Force on Preventive Health Care

189. Screening for thyroid dysfunction and treatment of screen-detected thyroid dysfunction in asymptomatic, community-dwelling adults: a systematic review (Full text)

Screening for thyroid dysfunction and treatment of screen-detected thyroid dysfunction in asymptomatic, community-dwelling adults: a systematic review This systematic review was conducted to inform the Canadian Task Force on Preventive Health Care recommendations on screening for thyroid dysfunction (TD). The review sought to answer key questions on the benefits and harms of screening for TD, patients' values and preferences for screening, and the benefits and harms of treating screen-detected

2019 EvidenceUpdates PubMed abstract

190. A systematic review and meta-analysis of the Kwak TIRADS for the diagnostic assessment of indeterminate thyroid nodules. (Abstract)

A systematic review and meta-analysis of the Kwak TIRADS for the diagnostic assessment of indeterminate thyroid nodules. To explore the diagnostic usefulness of the Thyroid Imaging Reporting and Data System (TIRADS) classification proposed by Kwak in indeterminate nodules using a systematic literature review.The PubMed, Cochrane database, ScienceDirect, and EMBASE databases were searched for relevant articles. A meta-analysis was performed to calculate pooled sensitivity, specificity, negative

2019 Clinical Radiology

191. Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis. (Abstract)

Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis. The incidence of papillary thyroid microcarcinoma (PTMC) has been increasing sharply, the current statement about whether PTMC patients should undergo radioactive iodine (RAI) remnant ablation is still controversial, mainly because it is uncertain whether RAI treatment can reduce the recurrence rate.To evaluate the effectiveness of RAI remnant ablation for thyroid cancer-related outcomes of PTMC patients.We (...) , the locoregional recurrence rates were 1.92 and 7.36% [risk ratio (RR)=0.45; 95% confidence interval (CI)=0.18-1.11; P=0.08] for patients with or without RAI treatment respectively, the distant metastasis rates were 1.39 and 2.46% (RR=0.64; 95% CI=0.28-1.48; P=0.30), and the thyroid cancer-related mortality rates were 0.98 and 1.76% (RR=0.68; 95% CI=0.22-2.09; P=0.50).For PTMC patients who have already treated by total thyroidectomy or near-total thyroidectomy, incremental RAI remnant ablation may

2019 Nuclear medicine communications

192. Commentary on: "A prognostic role for non-thyroidal illness syndrome in chronic renal failure: A systematic review and meta-analysis". (Abstract)

Commentary on: "A prognostic role for non-thyroidal illness syndrome in chronic renal failure: A systematic review and meta-analysis". 31550551 2019 11 25 2019 11 25 1743-9159 71 2019 11 International journal of surgery (London, England) Int J Surg Commentary on: "A prognostic role for non-thyroidal illness syndrome in chronic renal failure: A systematic review and meta-analysis". 100 S1743-9191(19)30252-3 10.1016/j.ijsu.2019.09.021 Majeed Numan N Department of Chemical Pathology, Army Medical

2019 International journal of surgery (London, England)

193. Correction to: Efficacy of radiofrequency ablation in autonomous functioning thyroid nodules. A systematic review and meta-analysis. (Full text)

Correction to: Efficacy of radiofrequency ablation in autonomous functioning thyroid nodules. A systematic review and meta-analysis. The authors of this paper declare that their correct family and first names and their correct affiliations are shown in this correction paper.

2019 Reviews in endocrine & metabolic disorders PubMed abstract

194. Reliability of Thyroid FNAC as a Single Diagnostic Modality: A Systematic Review. (Abstract)

Reliability of Thyroid FNAC as a Single Diagnostic Modality: A Systematic Review. To determine the reliability of thyroid FNAC as a single diagnostic modality in the case of nodular neoplastic lesions of the thyroid. Multiple databases were searched using the MESH terms thyroid*lesion*nodule*neoplasm*fine needle aspiration*histopathology*correlation. Meta analyses, RCTs, cohort or case control studies and case series were searched. 61 studies were examined to verify the search results after (...) applying the inclusion and exclusion criteria. 422 studies were excluded after the first screening, leaving 61 full text articles. These were further analyzed for outcomes, and ultimately 9 studies were chosen for the final synthesis on the basis of clear recommendations given. FNAC as a single modality for the diagnosis of nodular neoplastic thyroid lesions is highly variable and therefore unreliable. The diagnostic yield may be improved if the Bethesda system of reporting is applied.© Association

2019 Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India

195. Correction to: Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis. (Full text)

Correction to: Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis. The original version of the article unfortunately contained an error.

2019 Endocrine pathology PubMed abstract

196. Smoking, alcohol and thyroid cancer occurrence: systematic review and meta-analysis of case-control studies. (Abstract)

Smoking, alcohol and thyroid cancer occurrence: systematic review and meta-analysis of case-control studies. English language case-control studies reporting on the association of thyroid cancer occurrence with smoking and alcohol drinking are summarized. Two independent researchers performed study selection and data extraction. Random effects model was applied and external adjustment was performed to control for important confounders. Twenty reports published between 1987 and 2007 were included (...) in quantitative synthesis. For smoking, mean association was inverse (odds ratio [OR]: 0.785; 95% CI: 0.701-0.879) remaining after adjustment for alcohol drinking; heterogeneity was moderate. For alcohol drinking, mean association was inverse (OR: 0.795; 95% CI: 0.660-0.958) (remaining after adjustment for smoking, OR: 0.832; 95% CI: 0.688-1.007); heterogeneity was large becoming moderate after adjustment. Data from case-control studies identified showed inverse mean association between thyroid cancer

2019 Expert review of endocrinology & metabolism

197. The Impact of Goiter and Thyroid Surgery on Goiter Related Esophageal Dysfunction. A Systematic Review. (Full text)

The Impact of Goiter and Thyroid Surgery on Goiter Related Esophageal Dysfunction. A Systematic Review. Background: Patients with goiter referred for thyroidectomy report swallowing difficulties. This might be associated with esophageal compression and deviation as this is present in a significant number of patients. Studies on how goiter and subsequently its treatment affect the esophagus are sparse and point in various directions. Our aim was to investigate, through a systematic review (...) . Conclusions: Thyroidectomy relieved patients with goiter from dysphagia, within 6 months of surgery probably via increase in the cross-sectional area of the esophagus. Attention to the impact by goiter on the esophagus is needed, and balanced and individualized information about the potential benefits and risks of thyroid surgery is crucial in the management of patients with goiter.

2019 Frontiers in endocrinology PubMed abstract

198. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. (Full text)

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Medullary thyroid cancer (MTC) is a rare form of cancer that affects patients' health-related quality of life (HRQoL) and survival. Cabozantinib (Cometriq®; Ipsen, Paris, France) and vandetanib (Caprelsa®; Sanofi Genzyme, Cambridge, MA, USA) are currently the treatment modality of choice for treating unresectable progressive and symptomatic MTC.(1 (...) -analysis (NMA)] was conducted to evaluate the clinical effectiveness and safety of cabozantinib and vandetanib. The economic analysis included a review of existing analyses and the development of a de novo model.The systematic review identified two placebo-controlled trials. The Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial evaluated the efficacy and safety of cabozantinib in patients with unresectable locally advanced, metastatic and progressive MTC. The ZETA trial

2019 Health technology assessment (Winchester, England) PubMed abstract

199. Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies. (Full text)

Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies. Epidemiological studies have suggested an association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) development. Other studies, however, have reported a protective role of HT against PTC progression. Through this updated meta-analysis, we aimed to clarify the effects of HT on the progression of PTC.We searched citation databases

2019 Endocrinology and metabolism (Seoul, Korea) PubMed abstract

200. miR-146a rs2910164 Polymorphism and Risk of Papillary Thyroid Carcinoma: A Meta-Analysis. (Abstract)

miR-146a rs2910164 Polymorphism and Risk of Papillary Thyroid Carcinoma: A Meta-Analysis. The presence of single nucleotide polymorphisms contributes to genetic diversity, and some are associated with cancer progression. Recent studies concerning the relationship between polymorphisms in miR-146a and the risk of papillary thyroid carcinoma (PTC) have produced conflicting results. Here, a meta-analysis of previous studies was performed to evaluate this relationship.Electronic databases

2019 Genetic testing and molecular biomarkers